Showing 1-2 of about 2 articles.
AzurRx BioPharma, Inc.
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”),...
AzurRx BioPharma, Inc.
On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsulesTrial completion and top-line...
Showing 1-2 of about 2 articles.
